Madam Speaker, obviously I empathize with the Montreal employees affected by this bad news. However, as we know, AstraZeneca's cuts to research and development activities worldwide, including in Canada unfortunately, is a business decision based on the global situation.
Nevertheless, AstraZeneca will continue its research and development activities in Canada in conjunction with our universities and other stakeholders. I would remind members that we have invested more in research and development than any other government in Canada's history, and the party opposite has always voted against these additional investments. We will continue along this path.